

JAAD Review Article Highlights Alopecia Areata Patients Generally Prefer Topical Treatments over Oral or Injectable Options

Epalinges, Switzerland, 29 November 2024 - - Legacy Healthcare, a Swiss-based biotechnology company developing first-in-class botanical drugs, today announced that Journal of the American Academy of Dermatology (JAAD), published a review article describing patient preferences for the treatment of alopecia areata.

"The article highlighted that patients generally preferred topical treatments over oral or injectable options and that their top preferences include hair regrowth efficacy, a favorable safety profile with minimal systemic risks, and convenient administration methods," commented Saad Harti, Chairman & CEO of Legacy Healthcare. "This aligns perfectly with the targeted product profile of CINAINU, our first botanical drug developed to treat children and adolescents with moderate to severe alopecia areata."

JAAD is the official scientific publication of the American Academy of Dermatology. To access the full review article by Carmichael AR, Lovell KK, Prieto K, Feldman SR, Pichardo RO, entitled "Patient preferences in the treatment of alopecia areata: a review of the literature", JAAD Reviews (2024), please click on the following link: <u>https://doi.org/10.1016/j.jdrv.2024.11.008</u>

About Legacy Healthcare

Legacy Healthcare is a Swiss-based biopharmaceutical company focused on leveraging the pleiotropic activity and strong safety profile of plants to develop prescription botanical drugs that address serious medical conditions. The company's first product candidate, CINAINU, has demonstrated strong safety and efficacy in a phase 2/3 study involving patients suffering from alopecia areata, a chronic autoimmune condition with highly damaging psycho-social issues that impact all who suffer from it, especially children.

For more information please visit www.legacyhealthcare.ch

Inquiries: contact@leagacyhealthcare.ch;